Answers are grounded in this paper and cite their sources.
Lung cancer represents the leading cause of cancer mortality worldwide, accounting for 1.2 million deaths each year. Improving survival in lung cancer is a major challenge for modern oncology considering that 5-year survival remains <15%, across all stages of disease and with <7% of patients alive 10 years after diagnosis. Because of the difficulties in significantly improving survival in locally advanced and metastatic non-small-cell lung cancer (NSCLC), diagnosis and treatment of early stages theoretically represent the most consistent possibility of modifying the outcome of NSCLC in terms of disease-free and overall survival.
No takes yet. Share an insight, caveat, or question.
Crinò et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: